Nls Pharmaceutics Ltd Financials
This page shows Nls Pharmaceutics Ltd (NLSP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Nls Pharmaceutics Ltd does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Nls Pharmaceutics Ltd passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Nls Pharmaceutics Ltd reported a net loss of $8.3M while operations used $2.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Nls Pharmaceutics Ltd's EBITDA was -$2.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 51.7% from the prior year.
Nls Pharmaceutics Ltd reported -$8.3M in net income in fiscal year 2025. This represents a decrease of 319.0% from the prior year.
Nls Pharmaceutics Ltd earned $2.16 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 11.1% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Nls Pharmaceutics Ltd recorded an outflow of $2.8M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 158.8% from the prior year.
Nls Pharmaceutics Ltd held $2.2M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Nls Pharmaceutics Ltd's ROE was -114.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Nls Pharmaceutics Ltd invested $1.1M in research and development in fiscal year 2025. This represents an increase of 13.5% from the prior year.
Nls Pharmaceutics Ltd invested $8K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 33.3% from the prior year.
Not reported for fiscal year 2025.
NLSP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $1.1M+13.5% | $992K-38.3% | $1.6M-82.1% | $9.0M+51.6% | $5.9M+5844.4% | $100K-88.9% | $898K+26.7% | $708K |
| SG&A Expenses | $1.3M+67.5% | $805K-39.3% | $1.3M-79.6% | $6.5M+9.5% | $5.9M+170.1% | $2.2M-33.3% | $3.3M+20.4% | $2.7M |
| Operating Income | -$2.6M-24.0% | -$2.1M+31.5% | -$3.0M+80.5% | -$15.5M-30.5% | -$11.9M-415.8% | -$2.3M | N/A | -$3.4M |
| Interest Expense | N/A | $45K-62.4% | $120K+26.0% | $95K+97.9% | $48K-44.6% | $87K+8649.2% | $992 | N/A |
| Net Income | -$8.3M-319.0% | -$2.0M+40.6% | -$3.3M+79.8% | -$16.5M-38.1% | -$11.9M-317.5% | -$2.9M | N/A | -$5.1M |
| EPS (Diluted) | $2.16-11.1% | $2.43 | $1.13+103.4% | -$33.52 | -$1.00 | -$0.41 | N/A | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
NLSP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $11.4M+1167.4% | $903K-51.1% | $1.8M-80.1% | $9.3M+60.9% | $5.8M+375.8% | $1.2M+74.0% | $696K | N/A |
| Current Assets | $3.2M+307.9% | $780K-57.2% | $1.8M-80.3% | $9.2M+61.6% | $5.7M+2809.4% | $197K-48.5% | $382K | N/A |
| Cash & Equivalents | $2.2M+238.6% | $650K-43.3% | $1.1M-87.2% | $8.9M+64.8% | $5.4M+5695.7% | $94K-57.5% | $220K+3198.4% | $7K |
| Goodwill | $1.7M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $4.2M-52.9% | $8.9M+192.4% | $3.0M-66.8% | $9.2M+75.5% | $5.2M-48.8% | $10.2M+48.5% | $6.9M | N/A |
| Current Liabilities | $4.2M-52.9% | $8.9M | N/A | $3.4M+39.8% | $2.4M-66.6% | $7.2M+78.5% | $4.0M | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | $113K | N/A | N/A |
| Total Equity | $7.3M+190.7% | -$8.0M-568.0% | -$1.2M-1178.4% | $111K-79.5% | $542K+106.0% | -$9.0M-45.6% | -$6.2M+30.0% | -$8.8M |
| Retained Earnings | -$84.9M-10.8% | -$76.6M-8.8% | -$70.4M-20.9% | -$58.2M-39.6% | -$41.7M-40.1% | -$29.8M-10.6% | -$26.9M | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable.
NLSP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.8M-159.5% | -$1.1M+69.0% | -$3.4M+75.2% | -$13.9M+7.1% | -$14.9M-1947.8% | -$729K-283.9% | -$190K+93.0% | -$2.7M |
| Capital Expenditures | $8K+33.3% | $6K0.0% | $6K | N/A | $40K | N/A | N/A | N/A |
| Free Cash Flow | -$2.8M-158.8% | -$1.1M+68.9% | -$3.5M | N/A | -$15.0M | N/A | N/A | N/A |
| Investing Cash Flow | $1.7M+28433.3% | -$6K-105.8% | $103K | N/A | -$40K | N/A | N/A | N/A |
| Financing Cash Flow | $2.6M+484.2% | $450K-84.2% | $2.8M-83.6% | $17.4M-14.5% | $20.3M+3939.1% | $504K+23.6% | $407K-27.0% | $558K |
| Dividends Paid | N/A | $2.1M | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Share Buybacks.
NLSP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -114.5% | N/A | N/A | -14861.0%-12658.5pp | -2202.5% | N/A | N/A | N/A |
| Return on Assets | -72.5%+16.2pp | -88.7%+91.7pp | -180.4%-2.6pp | -177.8%+29.4pp | -207.2%+28.9pp | -236.2% | N/A | N/A |
| Current Ratio | 0.76+0.7x | 0.09 | N/A | 2.75+0.4x | 2.38+2.4x | 0.03-0.1x | 0.09 | N/A |
| Debt-to-Equity | 0.58 | N/A | N/A | 82.57+72.9x | 9.63 | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Note: The current ratio is below 1.0 (0.76), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Nls Pharmaceutics Ltd Ranks
Frequently Asked Questions
Is Nls Pharmaceutics Ltd profitable?
No, Nls Pharmaceutics Ltd (NLSP) reported a net income of -$8.3M in fiscal year 2025.
What is Nls Pharmaceutics Ltd's EBITDA?
Nls Pharmaceutics Ltd (NLSP) had EBITDA of -$2.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Nls Pharmaceutics Ltd's return on equity (ROE)?
Nls Pharmaceutics Ltd (NLSP) has a return on equity of -114.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Nls Pharmaceutics Ltd's free cash flow?
Nls Pharmaceutics Ltd (NLSP) recorded an outflow of $2.8M in free cash flow during fiscal year 2025. This represents a -158.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Nls Pharmaceutics Ltd's operating cash flow?
Nls Pharmaceutics Ltd (NLSP) recorded an outflow of $2.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Nls Pharmaceutics Ltd's total assets?
Nls Pharmaceutics Ltd (NLSP) had $11.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Nls Pharmaceutics Ltd's capital expenditures?
Nls Pharmaceutics Ltd (NLSP) invested $8K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Nls Pharmaceutics Ltd spend on research and development?
Nls Pharmaceutics Ltd (NLSP) invested $1.1M in research and development during fiscal year 2025.
What is Nls Pharmaceutics Ltd's current ratio?
Nls Pharmaceutics Ltd (NLSP) had a current ratio of 0.76 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Nls Pharmaceutics Ltd's debt-to-equity ratio?
Nls Pharmaceutics Ltd (NLSP) had a debt-to-equity ratio of 0.58 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Nls Pharmaceutics Ltd's return on assets (ROA)?
Nls Pharmaceutics Ltd (NLSP) had a return on assets of -72.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Nls Pharmaceutics Ltd's cash runway?
Based on fiscal year 2025 data, Nls Pharmaceutics Ltd (NLSP) had $2.2M in cash against an annual operating cash burn of $2.8M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Nls Pharmaceutics Ltd's Piotroski F-Score?
Nls Pharmaceutics Ltd (NLSP) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Nls Pharmaceutics Ltd's earnings high quality?
Nls Pharmaceutics Ltd (NLSP) reported a net loss of $8.3M while operations used $2.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.